Status:
TERMINATED
Cognitive Control and Physical Exercise
Lead Sponsor:
Columbia University
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Cognitive Function
Day-to-Day Function
Eligibility:
All Genders
60-75 years
Phase:
NA
Brief Summary
The purpose of this study is to test the hypothesis that aerobic exercise and a computer-based cognitive intervention leads to improved cognitive function accompanied by increases in gray matter densi...
Detailed Description
Epidemiological evidence suggest that a set of lifetime exposures including educational and occupational attainment and leisure activities later in life are associated with more preserved cognitive an...
Eligibility Criteria
Inclusion
- Age 60-75
- English-speaking
- Strongly right-handed
- BMI \> 18.5 and \< 32
- Post-menopausal (women only): no estrogen replacement therapy
- Sedentary: VO2max \< 36 ml/kg/min for men age 60-75; \< 29 ml/kg/min for women age 60-75 (determined using Jones Formula Men = (60-(0.55\*AGE)) Women = (48-(.37\*AGE))
Exclusion
- MRI contraindications (e.g., metallic implants, pacemaker, weight \> 350 lbs, waist \> 55")
- Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective lenses
- Objective cognitive impairment
- Ischemic changes, abnormal blood pressure responses, or any significant ectopy during aerobic capacity testing
- Cardiovascular disease
- Uncontrolled high blood pressure (systolic blood pressure ≥ 180 mmHg; or diastolic blood pressure ≥ 105 mmHg on two measures)
- Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma
- Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II).
- HIV infection
- Pregnant or lactating (participation allowed 3 months after ceasing lactation
- Other medical disorders judge to interfere with study
- Medications that target CNS (e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month
- Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen ablation/deprivation hormonal therapies
- Any history of psychosis or electroconvulsive therapy
- Psychotic disorder (lifetime)
- Current or recent (within past 12 months) alcohol or substance abuse or dependence. Recent use (past month) of recreational drugs.
- Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury, mental retardation
- Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying lesion (≥ 2 cubic cm). Other findings, e.g., periventricular caps or small white matter hyperintensities, do not result in exclusion
- Diagnosed learning disability, dyslexia
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01183819
Start Date
February 1 2010
End Date
June 1 2015
Last Update
August 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032